{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:36:05Z","timestamp":1756895765283},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.dsx.2017.12.005","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T13:41:02Z","timestamp":1513863662000},"page":"305-308","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Renin angiotensin-aldosterone system (RAAS) blockers usage among type II diabetes mellitus patients\u2014A Retrospective Study"],"prefix":"10.1016","volume":"12","author":[{"given":"Yen Ping","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh Pandian","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi Ping","family":"Heng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Kalaiselvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Wen","family":"Teh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kin Man","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Faiz Bin Abdul","family":"Hadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosmaliza Bt","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2017.12.005_bib0005","series-title":"Global report on diabetes WHO","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.dsx.2017.12.005_bib0010","series-title":"National Health and Morbidity Survey 2015 (NHMS 2015). Vol. II: non-communicable diseases, risk factors & other health problems","author":"Institute of Public Health","year":"2015"},{"issue":"7","key":"10.1016\/j.dsx.2017.12.005_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ejcn.2017.44","article-title":"Type 2 diabetes mellitus in Malaysia: current trends and risk factors","volume":"71","author":"Tee","year":"2017","journal-title":"Eur J Clin Nutr"},{"issue":"5","key":"10.1016\/j.dsx.2017.12.005_bib0020","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.2337\/diabetes.51.5.1580","article-title":"International Diabetic Nephropathy Study Group The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes","volume":"51","author":"Drummond","year":"2002","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.dsx.2017.12.005_bib0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/kisup.2013.80","article-title":"Slowing progression of chronic kidney disease","volume":"3","author":"Drawz","year":"2011","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"10.1016\/j.dsx.2017.12.005_bib0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"Evidence-based guidelines for the management of high blood pressure in adults. report from the panel members appointed to the eighth joint national committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.dsx.2017.12.005_bib0035","article-title":"KDIGO clinical practice guideline for the management of blood pressure in CKD","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1016\/j.dsx.2017.12.005_bib0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting enzyme inhibitor, Ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Eng J Med"},{"issue":"9200","key":"10.1016\/j.dsx.2017.12.005_bib0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Heart Outcomes Prevention Evaluation Study Investigators Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.dsx.2017.12.005_bib0050","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Eng J Med"},{"issue":"12","key":"10.1016\/j.dsx.2017.12.005_bib0055","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Eng J Med"},{"issue":"15","key":"10.1016\/j.dsx.2017.12.005_bib0060","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"The ONTARGET investigators Telmisartan, Ramipril or both in patients at high risk for vascular events","volume":"358","year":"2008","journal-title":"N Eng J Med"},{"issue":"19","key":"10.1016\/j.dsx.2017.12.005_bib0065","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Eng J Med"},{"issue":"9","key":"10.1016\/j.dsx.2017.12.005_bib0070","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1525-1497.2005.0170.x","article-title":"Patterns of anti-hypertensive therapy among patients with diabetes","volume":"20","author":"Johnson","year":"2005","journal-title":"J Gen Intern Med"},{"issue":"2","key":"10.1016\/j.dsx.2017.12.005_bib0075","doi-asserted-by":"crossref","first-page":"e0116970","DOI":"10.1371\/journal.pone.0116970","article-title":"ACEI or ARB underused in patients with type 2 diabetes in Chinese population (CCMR-3\u2009B study)","volume":"10","author":"Xie","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.dsx.2017.12.005_bib0080","first-page":"109","article-title":"Prescribing pattern of antihypertensive drug in diabetic patients of Southern Province","volume":"56","author":"Alavudeen","year":"2015","journal-title":"Kingdom of Saudi Arabia Ars Pharm"},{"issue":"3","key":"10.1016\/j.dsx.2017.12.005_bib0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.dsx.2012.03.001","article-title":"Prevalence of hypertension, control of blood pressure and treatment in hypertension with type 2 diabetes in Hospital Universiti Sains Malaysia","volume":"5","author":"Abougalambou","year":"2011","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.dsx.2017.12.005_bib0090","first-page":"T2","article-title":"Prescription pattern of antihypertensive agents in DM patients visiting tertiary care centre in North India","author":"Dhanaraj","year":"2012","journal-title":"Int J Hypertens"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402117303697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402117303697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T00:31:24Z","timestamp":1535157084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402117303697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1871402117303697"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2017.12.005","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin angiotensin-aldosterone system (RAAS) blockers usage among type II diabetes mellitus patients\u2014A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2017.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}